Austin R. Pantel

Hospital of the University of Pennsylvania — United States

Medicine · Health Sciences

25h-index2.5kcitations197works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Medical Imaging Techniques and Applications(71), Ovarian cancer diagnosis and treatment(38), Radiopharmaceutical Chemistry and Applications(38), Radiomics and Machine Learning in Medical Imaging(33), Prostate Cancer Treatment and Research(27)

Publications197 total

Supplemental Figure S2 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S3 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S5 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S1 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Table S2 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S4 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Figure S6 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
Supplemental Table S1 from [<sup>18</sup>F]FluorThanatrace ([<sup>18</sup>F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
2025Open Access
First-in-Human Biodistribution and Dosimetry of [11C]Trimethoprim
Molecular Imaging and Biology·2025Open Access
Creating a dedicated radionuclide therapy clinic and leveraging telemedicine to increase access to radiopharmaceutical therapies
Clinical Imaging·2025
Hypercalcemia Secondary to Silicone Inflammation Shown on FDG PET/CT
Clinical Nuclear Medicine·2025
Pixelprint <sup>PET</sup> - 3D-Printed Anthropomorphic Phantoms for Quantitative PET/CT Imaging
2025
PMSA-avid intracranial lesions are more likely to reflect metastases in men with polymetastatic disease
Clinical Imaging·2025
Frequency, Quality, and Content of Feedback to Radiology Residents: A Needs Assessment
Academic Radiology·2025
L-5-[11C]-glutamine PET of breast cancer: Preclinical studies in mouse models
Nuclear Medicine and Biology·2025Open Access
Automated Tools to Analyze FES PET: Translational Potential to Guide Therapy in Estrogen Receptor Positive Breast Cancer
Radiology Imaging Cancer·2025Open Access
Abstract P2-07-04: [18F]FluorThanatrace PET imaging correlates with response to PARP inhibitors in breast cancer: a pilot study
Clinical Cancer Research·2025
Dual-Tracer Imaging on a Long–Axial-Field-of-View PET: A Proof-of-Principle Study with [<sup>18</sup>F]FGln and [<sup>18</sup>F]FDG
Journal of Nuclear Medicine·2025Open Access
Extraordinarily High 99mTcO4− Activity in Meckel’s Diverticulum Relative to the Stomach
Clinical Nuclear Medicine·2025
[18F]FluorThanatrace PET imaging as a biomarker of response to PARP inhibitors in breast cancer
Communications Medicine·2025· 5 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

David A. Mankoff(21), Joel S. Karp(12), Varsha Viswanath(12), Robert K. Doot(11), Daniel A. Pryma(7), Margaret E. Daube-Witherspoon(5), Erin K. Schubert(5), Michael D. Farwell(5), Robert H. Mach(5), Hsiaoju Lee(4), Sophia R. O’Brien(4), Mark Muzi(4), Lorenzo Nardo(4), Mehran Makvandi(3), Fiona Simpkins(3), Lilie L. Lin(3), Rong Zhou(3), Shihong Li(3), Elizabeth S. McDonald(3), Clemens Mingels(3)